DSG and Ovation Partner in Serveral Studies
DSG is one of Ovation’s preferred providers for Phase I studies.
Malvern, PA-May 13, 2008-DSG (www.dsg-us.com), a leading EDC and clinical software technology provider, today announced that Ovation Pharmaceuticals (www.ovationpharma.com) is using DSG’s award-winning eCaseLink EDC software to conduct several Phase I clinical trials. DSG is one of Ovation’s preferred providers for EDC software for these studies.
To date, Ovation has used eCaseLink for five Phase I studies, and has seven Phase I studies underway or planned for 2008 and six Phase I studies planned for 2009.
“We looked at a number of vendors before choosing to work with DSG. We chose DSG’s eCaseLink for a number of our Phase I studies because it is very intuitive and user-friendly, and provides exceptionally clean data, as well as real-time data and monitoring. This translated directly into significant time and cost-savings for us,” said Robert Anders, vice president of Ovation’s clinical operations. “DSG supported very tight timelines for our Phase I studies.”
“We are pleased to work with Ovation, which continues to bring important therapies to market for very specific, high-need patient groups. The company has an impressive new product pipeline and we are proud to be a part of that process,” said Tony Varano, chief executive officer of DSG. “To complement our award-winning eCaseLink software, we are providing our EDC-focused data management services to increase their trial efficiencies even more.”
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Beyond the Molecule: How Human-Centered Design Unlocks AI's Promise in Pharma
June 23rd 2025How human-centered AI that is focused on customer, user, and employee experience can drive real transformation in clinical trials and beyond by aligning intelligent technologies with the people who use them.
2025 DIA Annual Meeting: Why AI and Automation Are Set to Become the New Normal in Clinical Research
June 20th 2025Peter Ronco, CEO, Emmes, shares his long-term vision for artificial intelligence in clinical research, from making automation routine to improving drug discovery, transforming regulatory oversight, reducing animal testing, and promoting ethical, equitable data use worldwide.
